Clinical trials: Relapse Management
Non-Hodgkin Lymphoma
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL…
- Trial name
- NCT00100737
- Testing
- interleukin-2, rituximab
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Chiron Corporation
Relapsed or Refractory Multiple Myeloma
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or…
- Trial name
- NCT07312188
- Testing
- F182112+P, F182112+CD38
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD